rilmenidine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: C1COC(NC(C2CC2)C2CC2)=N1
  • InChIKey: CQXADFVORZEARL-UHFFFAOYSA-N
  • Mol. Mass: 180.25
  • ALogP: 1.15
  • ChEMBL Molecule:
    rilmenidine  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

2-(n-(dicyclopropylmethyl)amino)oxazoline | 2-(n-(dicyclopropylmethyl)amino)oxazoline phosphate salt | 2-oxazolamine, n-(dicyclopropylmethyl)-4,5-dihydro- | hyperium | oxaminozoline | rilmenidene | rilmenidine | rilmenidine dihydrogen phosphate | rilmenidine phosphate | s3341 | s 3341 | s-3341 | s-3341-3

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Atherosclerosis (Phase 4)

Hypertension (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue